LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer

LSKB's rivoceranib has missed its endpoint in a Phase III trial in gastric cancer, but the company remains hopeful it will still be able to get FDA approval of the VEGFR-2 inhibitor in this setting, possibly helped by a small additional trial, although there will be a delay. Studies in other potential indications are also ongoing.